MDS Nordion wins imaging supply deal with Molecular Insight:
This article was originally published in Clinica
Radiotherapy company MDS Nordion has secured a six-year renewable contract to manufacture and supply Zemiva, a cardiac imaging agent, to Cambridge, Massachusetts-based Molecular Insight Pharmaceuticals. The product's first indication will be for the rapid diagnosis of cardiac ischaemia in acute care settings. Evidence suggests that Zemiva administered to patients at rest can detect ischaemia by imaging patients up to 30 hours after a cardiac event has occurred. It is estimated that 5-8 million patients in the US each year need to have determined whether their chest pain is caused by insufficient blood flow to the heart (a heart attack), according to Ottawa, Canada-based MDS.